AdAlta Ltd

[Available On-Demand]
Search General Info
Search Education
Search Partnering Companies
AdAlta is a late pre-clinical stage company using its i-body platform to discover and develop next generation protein therapeutics addressing drug targets that are challenging for traditional antibody technologies.

AdAlta's internal product development pipeline is focussed on G-protein coupled receptors (GPCRs). Lead product candidate AD-214 is a CXCR4 antagonist and is poised to enter initial human clinical trials in mid-2020 in orphan disease idiopathic pulmonary fibrosis (IPF). AD-214 has potential application in a wide range of fibrotic diseases.

AdAlta also works to discover and co-develop i-body products against targets brought by co-development partners, such as our existing relationship with GE Healthcare. These may be GPCRs, ion channels or other challenging targets.

AdAlta is listed on the ASX (ASX:1AD)
Ticker:
1AD
Exchange:
ASX
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Australia
Year Founded:
2006
Main Therapeutic Focus:
Lead Product in Development:
AD-214
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
One
Speaker
photo
CEO and Managing Director
AdAlta Ltd